Products with
Inhibitors bioactivity
Cat.No.
|
Product Name
|
BCN1247 |
Isorhamnetin-3-O-beta-D-Glucoside
|
Isorhamnetine-3-O-rutinoside inhibits the activity of alpha-glucosidase from rat intestine; it exhibits a potent rat lens aldose reductase (RLAR) inhibition in vitro, its IC(50) being 1.4 microM and has inhibitory effects of sorbitol accumulation, suggests that it is a leading compound for further study as a new drug for the prevention and/or treatment of diabetes and its complications. |
BCN1255 |
Catharanthine
|
Catharanthine inhibits nicotinic receptor mediated diaphragm contractions with IC50 of 59.6 μM, it dilates small mesenteric arteries and decreases heart rate and cardiac contractility by inhibition of voltage-operated calcium channels on vascular smooth muscle cells and cardiomyocytes. |
BCN1268 |
Herbacetin
|
Herbacetin, a novel Met inhibitor with a potential utility in cancer therapeutics, suppresses the HGF-induced motility of human breast cancer MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation. Herbacetin exerts an anti-inflammatory effect through suppression of LPS-induced JNK and NF-κB signaling pathways and diminished production of proinflammatory cytokines and mediators. Herbacetin also has a strong ability to scavenge free radical and inhibit oxidative protein damage. |
BCN1274 |
Shionone
|
Shionone has anti-inflammatory effect, the mechanism is related to decrease the phosphorylation level of ERK1/2 protein and IκBα and the protein expression of i NOS.
It can inhibit the activity of ubiquitin-specific protease 2 (USP2) and provide a lead compound for future development of new USP2 inhibitors. |
BCN1280 |
Cantharidin
|
Cantharidin, a natural toxicant of blister beetles, is a strong inhibitor of protein phosphatases types 1 (PP1) and 2A (PP2A), and is a novel and potent multidrug resistance (MDR) reversal agent. Cantharidin has anti-tumor activity, it causes oxidative stress that provokes DNA damage and p53-dependent apoptosis, it impairs cell migration and invasion by suppressing MMP-2 and -9 through PI3K/NF-κB signaling pathways. |